regorafenib

AKT serine/threonine kinase 1 ; Homo sapiens







19 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35126712 Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. 2022 Mar 6
2 35244188 DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. 2022 Apr 1
3 35502476 Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. 2022 May 2 3
4 34596810 Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. 2021 Nov 3
5 32457362 Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. 2020 Aug 2
6 30929918 Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. 2019 May 14 1
7 31163381 Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. 2019 Aug 2
8 31238539 Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. 2019 Jun 24 2
9 31501414 A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. 2019 Sep 9 1
10 29359239 The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. 2018 May 1
11 29609689 Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy. 2018 Apr 2 1
12 29783729 Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. 2018 May 19 2
13 28000898 Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells. 2017 Feb 1
14 28166200 Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. 2017 Jun 22 1
15 28978118 Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. 2017 Sep 15 1
16 26419617 Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. 2016 May 1
17 25838391 Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 2015 Jul 1 1
18 25132955 Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. 2014 1
19 23877009 Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. 2013 Oct 1